Search Results

Two-Year Outcomes Published From Elixir Medical's DESolve Nx Trial

March 24, 2016—Two-year outcomes from the DESolve Nx trial were published by Alexandre Abizaid, MD, et al in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2016;9:565–574). The study is evaluating the late multimodality imaging and clinical outcomes of Elixir Medical’s poly-l-lactic-acid–based Desolve novolimus-eluting bioresorbable coronary scaffold system for the treatment of de novo coronary lesions.

Reva Medical Presents Initial Clinical Results for Fantom Scaffold

May 21, 2015—Reva Medical, Inc. announced that initial clinical data on a subset of patients treated with the Fantom sirolimus-eluting bioresorbable scaffold were presented by Alexandre Abizaid, MD, during the Cardiovascular Innovations Pipeline session at the EuroPCR 2015 conference held May 19–22 in Paris, France.

First Patients Enrolled in Trial of Reva Medical's Fantom Bioresorbable Scaffold

December 3, 2014—Reva Medical, Inc. announced the initiation of patient enrollment in the clinical trial program for the company’s Fantom bioresorbable drug-eluting scaffold.

Three-Year Results Presented for the Elixir Medical's Desolve Novolimus-Eluting Bioresorbable Coronary Scaffold System

October 15, 2015—Elixir Medical Corporation announced 3-year clinical and imaging results from the DESolve Nx international pivotal clinical trial for the company’s CE Mark approved, fully bioresorbable Desolve novolimus-eluting coronary scaffold system.  Prof.

First-in-Man Sesame Stent Trial Results Published

November 16, 2010—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the publication of results from the first-in-man trial of the Sesame self-expanding, super-elastic, all-metal endoprosthesis stent (Palmaz Scientific/Advanced BioProsthetic Surfaces, Ltd., San Antonio, TX) that was used in patients undergoing angioplasty of degenerated saphenous vein graft (SVG) lesions.

Reva Presents 12-Month RESTORE Data and ReZolve2 Program Update

May 21, 2013—At EuroPCR 2013 in Paris, France, Reva Medical, Inc. (San Diego, CA) released 12-month data on a subset of patients enrolled in the RESTORE clinical trial.

MASTER Trial Begins for InspireMD's MGuard Stent System

July 26, 2011—InspireMD, Inc. (Tel Aviv, Israel) announced commencement of the MASTER (MGuard for Acute ST-Elevation Reperfusion) trial with the initial patient enrollment at the Krakow Specialist Hospital–John Paul II in Krakow, Poland.

Enrollment Begins in REMEDEE Trial of OrbusNeich's Combo DES

December 1, 2009—OrbusNeich, Inc. (Fort Lauderdale, FL) announced the initiation of patient enrollment in the REMEDEE (Randomized Evaluation of an Abluminal Sirolimus-Coated Bio-Engineered Stent) clinical trial of the company's Combo bioengineered sirolimus-eluting stent.

FDA Grants Breakthrough Device Designation for Concept Medical's MagicTouch Sirolimus-Coated Balloon

May 2, 2019—Concept Medical Inc. has been granted Breakthrough Device Designation from the FDA for the company's MagicTouch sirolimus drug-coated balloon (DCB) catheter, for the treatment of coronary in-stent restenosis (ISR).

Concept Medical’s MagicTouch Sirolimus-Coated Balloon Approved in Brazil

September 19, 2025—Concept Medical Group announced that its flagship MagicTouch sirolimus-coated balloon for the treatment of coronary artery disease has received commercial approval from Brazil’s Health Surveillance Agency—ANVISA, Agência Nacional de Vigilância Sanitária.

Reva Medical Expands FANTOM II Clinical Trial to Australia

May 14, 2015—Reva Medical, Inc. announced the expansion of the FANTOM II clinical trial to Australia, where the trial is enrolling patients for treatment with the Fantom sirolimus-eluting bioresorbable scaffold.

AngioScore Begins FIH Study of Drug-Coated AngioSculpt Scoring Balloon Catheter

December 14, 2011—AngioScore, Inc. (Fremont, CA) announced the commencement of enrollment in the Drug-Coated AngioSculpt Scoring Balloon Catheter First-in-Human (FIH) study.

Reva Initiates Enrollment in Trial of the ReZolve2 Bioresorbable Coronary Scaffold

March 28, 2013—Reva Medical, Inc. (San Diego, CA) announced that it has initiated patient enrollment in its clinical trial evaluating its ReZolve2 bioresorbable, sirolimus-eluting coronary scaffold.

Medtronic to Initiate Clinical Study of Drug-Filled Stent

March 14, 2015—Medtronic plc announced the preclinical outcomes of its drug-filled stent (DFS) at the 64th annual scientific session of the American College of Cardiology (ACC).

Initial Clinical Enrollment Completed in Study of Reva's ReZolve Scaffold

July 12, 2012—Reva Medical, Inc. (San Diego, CA) announced that it has completed clinical enrollment with the ReZolve drug-eluting bioresorbable scaffold.

Enrollment Completed for First-in-Human Study of AngioScore's AngioSculpt

June 19, 2013—AngioScore, Inc. (Fremont, CA) announced the completion of enrollment in the PATENT-C first-in-human (FIH) study of the company's drug-coated AngioSculpt scoring balloon catheter.

CE Mark Approval Granted for Elixir's Desyne Novolimus-Eluting Stent

May 23, 2011—Elixir Medical Corporation (Sunnyvale, CA) announced that it has received CE Mark approval for its Desyne novolimus-eluting coronary stent system for treating coronary artery disease.

FANTOM II Results Presented for Reva Medical's Fantom Bioresorbable Vascular Scaffold

October 31, 2016—The FANTOM II study was presented during the First Report Investigations presentations on bioresorbable stent technologies at TCT 2016, the 28th annual Transcatheter Cardiovascular Therapeutics scientific symposium in Washington, DC.